Source: iQoncept / Shutterstock
Agile Therapeutics (NASDAQ:AGRX) has just unveiled its financial report for the fourth quarter of 2023.
- With earnings per share standing at -$1.46, Agile Therapeutics fell short of the analyst consensus of -92 cents for EPS.
- The reported revenue amounted to $3.62 million.
- Regrettably, this figure strayed significantly from the anticipated revenue of $4.07 million, reflecting an 11.18% deviation.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/agrx-stock-earnings-agile-therapeutics-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
